Jin Medical International EBIT

The latest EBIT for ZJYL is $1.8M as of September 2025. That compares with $4.1M in the prior-year period — down 55.5% year over year. That is above the sector sector average of $-77M. Investors often review this figure alongside Jin Medical International's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZJYL's EBIT moved from $4.1M to $1.8M — a 55.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jin Medical International's operating scale or balance-sheet position.

Against its sector companies, ZJYL currently prints $1.8M for EBIT, while the sector average sits near $-77M. That is roughly 102.4% above the sector mean. Large gaps often invite a closer look at Jin Medical International's growth, margins, and balance sheet.

A EBIT figure of $1.8M for ZJYL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-77M. Explore the charts below for those layers of context.

After noting ZJYL's EBIT ($1.8M), review year-over-year change from $4.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.